Characterization of participants with elevated bleeding rates responding to prophylactic marstacimab treatment in the phase 3 BASIS trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4838
Abstract: Background Marstacimab, a monoclonal antibody targeting tissue factor pathway inhibitor to reduce inhibition of the extrinsic coagulation pathway and rebalance hemostasis, is approved for prophylaxis in patients with hemophilia A (HA) or B (HB) without… read more here.
Keywords: abr; treatment; pts elevated; target ... See more keywords